Cyclacel Pharmaceuticals (NASDAQ:CYCC) Now Covered by Analysts at StockNews.com

Analysts at StockNews.com began coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) in a report released on Tuesday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Several other research analysts also recently commented on the stock. Brookline Capital Management downgraded shares of Cyclacel Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, December 19th. Roth Mkm increased their target price on shares of Cyclacel Pharmaceuticals from $16.00 to $21.00 and gave the stock a “buy” rating in a report on Tuesday, December 19th.

Cyclacel Pharmaceuticals Price Performance

Shares of NASDAQ CYCC opened at $1.95 on Tuesday. The stock has a market capitalization of $2.57 million, a P/E ratio of -0.07 and a beta of 0.54. Cyclacel Pharmaceuticals has a one year low of $1.52 and a one year high of $13.20. The firm’s 50 day simple moving average is $2.36 and its two-hundred day simple moving average is $3.98.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last posted its quarterly earnings results on Tuesday, March 19th. The biotechnology company reported ($6.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($6.35) by $0.12. The business had revenue of $0.03 million for the quarter. As a group, equities analysts expect that Cyclacel Pharmaceuticals will post -18.7 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cyclacel Pharmaceuticals

Large investors have recently modified their holdings of the stock. Renaissance Technologies LLC bought a new stake in shares of Cyclacel Pharmaceuticals during the second quarter valued at approximately $68,000. Virtu Financial LLC purchased a new position in Cyclacel Pharmaceuticals during the second quarter valued at $33,000. Millennium Management LLC bought a new stake in shares of Cyclacel Pharmaceuticals during the 2nd quarter valued at $113,000. Two Sigma Investments LP purchased a new stake in shares of Cyclacel Pharmaceuticals in the 3rd quarter worth about $98,000. Finally, HRT Financial LP bought a new position in shares of Cyclacel Pharmaceuticals in the 4th quarter worth about $27,000. Institutional investors own 23.58% of the company’s stock.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors.